A phase II trial was conducted to determine the efficacy and toxicity of the addition of interferon-alpha 2b (IFN-alpha) to the chemotherapy combination of dacarbazine (DTIC), carmustine (BCNU), cisplatin and tamoxifen (DBCT), in patients with stage III or IV melanoma. Treatment consisted of DTIC 220 mg/m2 and cisplatin 25 mg/m2 intravenously on days 1-3, BCNU 100 mg/m2 IV on day 1 only, tamoxifen 20 mg orally twice daily and IFN-alpha 5 x 10(6) units/m2 subcutaneously on days 1-5. Cycles were repeated every 4 weeks. All patients received a loading dose of tamoxifen 100 mg orally twice daily for 5 days before the first course of therapy. Of the 24 patients treated, three (13%) achieved a complete response (CR) and six (25%) a partial response (PR), for an overall response rate of 38% (95% confidence interval, 17-58%). Two patients, one who achieved a clinical CR and one a PR, had pathologically confirmed complete responses. Severe myelosuppression occurred in 47% of cycles and constitutional symptoms were common. Overall, the addition of IFN-alpha to the DBCT regimen did not appear to enhance the response rate and may have increased toxicity.

译文

进行了II期试验,以确定在达卡巴嗪 (DTIC),卡莫司汀 (BCNU),顺铂和他莫昔芬 (DBCT) 的化疗组合中添加干扰素 α2b (IFN-α) 的疗效和毒性。III或IV期黑色素瘤患者。治疗包括在第1-3天静脉注射DTIC 220 mg/m2和顺铂25 mg/m2,仅在第1天静脉注射BCNU 100 mg/m2,他莫昔芬20 mg每天口服两次,在第1-5天皮下注射IFN-α5 × 10(6) 单位/m2。每4周重复一次周期。所有患者接受负荷剂量的他莫昔芬100 mg口服,每日两次,治疗前5天。在接受治疗的24例患者中,3例 (13% 例) 达到完全缓解 (CR),6例 (25% 例) 达到部分缓解 (PR),总缓解率为38% (95% 置信区间17-58%)。两名患者,其中一名获得了临床CR,一名获得了PR,经病理证实完全缓解。严重的骨髓抑制发生在47% 的周期和全身症状是常见的。总体而言,在DBCT方案中添加IFN-α 似乎并未增强反应率,并且可能具有增加的毒性。

+1
+2
100研值 100研值 ¥99课程
检索文献一次
下载文献一次

去下载>

成功解锁2个技能,为你点赞

《SCI写作十大必备语法》
解决你的SCI语法难题!

技能熟练度+1

视频课《玩转文献检索》
让你成为检索达人!

恭喜完成新手挑战

手机微信扫一扫,添加好友领取

免费领《Endnote文献管理工具+教程》

微信扫码, 免费领取

手机登录

获取验证码
登录